Vesalius and SRIW lead €10m series A round in Euroscreen

Other investors in the round included Life Sciences Research Partners VZW, Societe de Participation et de Gestion, Hunza Ventures and existing shareholders Fortis Private Equity, Compagnie du Bois Sauvage, Ackermans & Van Haaren and individuals.

Vesalius sourced equity from Vesalius Biocapital II in exchange for preferred stock.

The new capital will support the development and phase I and II of clinical trials of ESN364, a treatment drug for endometriosis.

Company
Euroscreen is a Brussels-based pharmaceuticals company focused on preclinical drug development and discovery. The company was founded as a spin-off from ULB (Universite Libre de Bruxelles). Its research centers around small molecule drug candidates for therapy in areas of inflammation, metabolism and sex hormone modulation. The company has research partnerships with corporates such as Boehringer-Ingelheim, Novartis and Pfizer

People
Alain Parthoens, managing partner, led the deal on behalf of Vesalius. Jean Combalbert is CEO of Euroscreen. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Now researching
• Benelux
• Healthcare
• Early-stage
• Belgium
• Neon Private Equity